Addex Therapeutics Shares Double Overnight as Neurosterix Raises $105 Million Series B for Schizophrenia Drug

Addex Therapeutics saw its shares surge 110% overnight to $6.00 after its former subsidiary Neurosterix disclosed a $105 million Series B fundraise following Phase 1 trials of NTX-253, an oral M4 receptor modulator targeting schizophrenia. Addex chose not to participate in the round, diluting its stake to 8.5%, a position valued at approximately $18.6 million, yet the residual holding was enough to lift the stock sharply as investors repriced the implied value of that minority interest.

Moderna held an Analyst Day in which management outlined a strategic shift toward oncology, centering on personalized cancer vaccines, while also detailing enhanced production capabilities. Investors tempered their enthusiasm by focusing on the implied rise in spending that would accompany the pipeline expansion.

Vivani Medical's stock also soared after the company reported positive topline results from its Phase 1 SLIM-1 trial of a subcutaneous semaglutide implant, showing weight-loss outcomes comparable to Wegovy with no treatment-related side effects. The company said it plans to advance the implant into a Phase 2 trial in 2027. Separately, Clene Nanomedicine announced a partnership with Veristat that cut biostatistical output time for its ALS new drug application by 80%, compressing a process that had taken up to six weeks down to one week.